Effect of anesthesia on the recurrence and metastasis of hepatocellular carcinoma

doi:10.3760/cma.j.cn371439-20221027-00024

Abstract

Abstract:

Hepatocellular carcinoma （HCC） is one of the leading causes of cancer death. There is a high risk of recurrence and metastasis after surgery. Anesthesia methods，anesthesia-related drugs and intraoperative anesthesia management can affect the biological behavior of HCC cells or the body's immunity，thus affecting the recurrence and metastasis of HCC. Paying attention to the effect of anesthesia on recurrence and metastasis of HCC and optimizing anesthesia management are expected to improve the long-term survival of patients.

Key words: Carcinoma, hepatocellular, Anesthesia, Neoplasm recurrence, Neoplasm metastasis

Ma Peihan, Zhang Lingming, Lu Ning, Zhang Mingxin. Effect of anesthesia on the recurrence and metastasis of hepatocellular carcinoma[J]. Journal of International Oncology, 2023, 50(2): 117-121.

References 50

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	斯迪克江·依布拉音, 刘洪亮, 吴晓龙, 等. 影响肝癌切除术预后的多因素分析[J]. 国际肿瘤学杂志, 2015, 42(3): 172-176. DOI: 10.3760/cma.j.issn.1673-422X.2015.03.004. doi: 10.3760/cma.j.issn.1673-422X.2015.03.004
[3]	Tabrizian P, Jibara G, Shrager B, et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis[J]. Ann Surg, 2015, 261(5): 947-955. DOI: 10.1097/SLA.000000000 0000710. doi: 10.1097/SLA.0000000000000710 pmid: 25010665
[4]	Plücker J, Wirsik NM, Ritter AS, et al. Anaesthesia as an influence in tumour progression[J]. Langenbecks Arch Surg, 2021, 406(5): 1283-1294. DOI: 10.1007/s00423-021-02078-z. doi: 10.1007/s00423-021-02078-z
[5]	Rossaint J, Zarbock A. Anesthesia-induced immune modulation[J]. Curr Opin Anaesthesiol, 2019, 32(6): 799-805. DOI: 10.1097/ACO.0000000000000790. doi: 10.1097/ACO.0000000000000790 pmid: 31464697
[6]	Boavista Barros Heil L, Leme Silva P, Ferreira Cruz F, et al. Im-munomodulatory effects of anesthetic agents in perioperative medicine[J]. Minerva Anestesiol, 2020, 86(2): 181-195. DOI: 10.23736/S0375-9393.19.13627-9. doi: 10.23736/S0375-9393.19.13627-9 pmid: 31680494
[7]	Zhang Y, Jing Y, Pan R, et al. Mechanisms of cancer inhibition by local anesthetics[J]. Front Pharmacol, 2021, 12: 770694. DOI: 10.3389/fphar.2021.770694. doi: 10.3389/fphar.2021.770694
[8]	Zhang H, Guo K, Sun X, et al. Impact of anesthesia methods on perioperative systemic inflammation and long-term outcomes in patients undergoing surgery for hepatocellular carcinoma: a propensity score-matched analysis[J]. Ann Transl Med, 2021, 9(1): 49. DOI: 10.21037/atm-20-3704. doi: 10.21037/atm-20-3704 pmid: 33553342
[9]	Wang X, Xie W, Gan S, et al. Effects of general anesthesia versus local anesthesia in primary hepatocellular carcinoma patients presenting for thermal ablation surgery: a multiple center retrospec-tive cohort study with propensity score matching[J]. Ann Transl Med, 2020, 8(6): 277. DOI: 10.21037/atm.2020.03.88. doi: 10.21037/atm.2020.03.88
[10]	Gao X, Mi Y, Guo N, et al. The mechanism of propofol in cancer development: an updated review[J]. Asia Pac J Clin Oncol, 2020, 16(2): e3-e11. DOI: 10.1111/ajco.13301. doi: 10.1111/ajco.13301
[11]	Li J, Liu M, Zeng B, et al. Propofol induces hepatocellular car-cinoma cell apoptosis via regulating miR-105/JAK2/STAT3 axis[J]. Cytokine, 2021, 148: 155649. DOI: 10.1016/j.cyto.2021.155649. doi: 10.1016/j.cyto.2021.155649
[12]	Liu Y, Wang X, Li H, et al. Propofol ameliorates the proliferation and epithelial-mesenchymal transition of hepatoma carcinoma cells via non-coding RNA activated by DNA damage (NORAD)/microRNA (miR)-556-3p/migration and invasion enhancer 1 (MIEN1) axis[J]. J Environ Pathol Toxicol Oncol, 2021, 40(4): 87-97. DOI: 10.1615/JEnvironPatholToxicolOncol.2021039471. doi: 10.1615/JEnvironPatholToxicolOncol.2021039471
[13]	Liu Y, Zhang N, Cao Q, et al. The effects of propofol on the growth behavior of hepatoma xenografts in Balb/c mice[J]. Biomed Pharmacother, 2017, 90: 47-52. DOI: 10.1016/j.biopha.2017.03. 041. doi: S0753-3322(17)30296-2 pmid: 28342365
[14]	Wang Y, Xu B, Zhou J, et al. Propofol activates AMPK to inhibit the growth of HepG2 cells in vitro and hepatocarcinogenesis in xenograft mouse tumor models by inducing autophagy[J]. J Gastrointest Oncol, 2020, 11(6): 1322-1332. DOI: 10.21037/jgo-20-472. doi: 10.21037/jgo-20-472
[15]	Ou W, Lv J, Zou X, et al. Propofol inhibits hepatocellular carci-noma growth and invasion through the HMGA2-mediated Wnt/β-catenin pathway[J]. Exp Ther Med, 2017, 13(5): 2501-2506. DOI: 10.3892/etm.2017.4253. doi: 10.3892/etm.2017.4253
[16]	Liu SQ, Zhang JL, Li ZW, et al. Propofol inhibits proliferation, migration, invasion and promotes apoptosis through down-regulating miR-374a in hepatocarcinoma cell lines[J]. Cell Physiol Biochem, 2018, 49(6): 2099-2110. DOI: 10.1159/000493814. doi: 10.1159/000493814
[17]	Gong T, Ning X, Deng Z, et al. Propofol-induced miR-219-5p inhibits growth and invasion of hepatocellular carcinoma through suppression of GPC3-mediated Wnt/β-catenin signalling activation[J]. J Cell Biochem, 2019, 120(10): 16934-16945. DOI: 10.1002/jcb.28952. doi: 10.1002/jcb.28952 pmid: 31104336
[18]	Fei G, Cao M, Ge C, et al. Propofol suppresses hepatocellular carcinoma by inhibiting NET1 through downregulating ERK/VEGF signaling pathway[J]. Sci Rep, 2020, 10(1): 11208. DOI: 10.1038/s41598-020-67693-0. doi: 10.1038/s41598-020-67693-0 pmid: 32641699
[19]	Song F, Liu J, Feng Y, et al. Propofol-induced HOXA11-AS pro-motes proliferation, migration and invasion, but inhibits apoptosis in hepatocellular carcinoma cells by targeting miR-4458[J]. Int J Mol Med, 2020, 46(3): 1135-1145. DOI: 10.3892/ijmm.2020.4667. doi: 10.3892/ijmm.2020.4667
[20]	Sun Y, Sun H. Propofol exerts anticancer activity on hepatocellular carcinoma cells by raising lncRNA DGCR5[J]. J Cell Physiol, 2020, 235(3): 2963-2972. DOI: 10.1002/jcp.29202. doi: 10.1002/jcp.29202 pmid: 31538334
[21]	Zheng H, Fu Y, Yang T. Propofol inhibits proliferation, migration, and invasion of hepatocellular carcinoma cells by downregulating Twist[J]. J Cell Biochem, 2019, 120(8): 12803-12809. DOI: 10.1002/jcb.28551. doi: 10.1002/jcb.28551 pmid: 30861184
[22]	Wang D, Xing N, Yang T, et al. Exosomal lncRNA H19 promotes the progression of hepatocellular carcinoma treated with propofol via miR-520a-3p/LIMK1 axis[J]. Cancer Med, 2020, 9(19): 7218-7230. DOI: 10.1002/cam4.3313. doi: 10.1002/cam4.3313
[23]	Lai HC, Lee MS, Lin C, et al. Propofol-based total intravenous anaesthesia is associated with better survival than desflurane anaesthesia in hepatectomy for hepatocellular carcinoma: a retrospective cohort study[J]. Br J Anaesth, 2019, 123(2): 151-160. DOI: 10.1016/j.bja.2019.04.057. doi: 10.1016/j.bja.2019.04.057
[24]	Koo BW, Lim DJ, Oh AY, et al. Retrospective comparison between the effects of propofol and inhalation anesthetics on postoperative recurrence of early- and intermediate-stage hepatocellular carcinoma[J]. Med Princ Pract, 2020, 29(5): 422-428. DOI: 10.1159/000506637. doi: 10.1159/000506637
[25]	黄凫卿, 倪强, 陈武荣. 丙泊酚与地氟醚麻醉对肝癌肝部分切除术后患者肝功能和远期预后影响的对比研究[J]. 海军医学杂志, 2020, 41(5): 600-602. DOI: 10.3969/j.issn.1009-0754.2020.05.035. doi: 10.3969/j.issn.1009-0754.2020.05.035
[26]	Nishiwada T, Kawaraguchi Y, Uemura K, et al. Effect of sevoflu-rane on human hepatocellular carcinoma HepG2 cells under conditions of high glucose and insulin[J]. J Anesth, 2015, 29(5): 805-808. DOI: 10.1007/s00540-015-2025-9. doi: 10.1007/s00540-015-2025-9 pmid: 25980989
[27]	Song G, Tian L, Cheng Y, et al. Antitumor activity of sevoflurane in HCC cell line is mediated by miR-29a-induced suppression of Dnmt3a[J]. J Cell Biochem, 2019, 120(10): 18152-18161. DOI: 10.1002/jcb.29121. doi: 10.1002/jcb.29121 pmid: 31190353
[28]	Cao Y, Lv W, Ding W, et al. Sevoflurane inhibits the proliferation and invasion of hepatocellular carcinoma cells through regulating the PTEN/Akt/GSK-3β/β-catenin signaling pathway by downregula-ting miR-25-3p[J]. Int J Mol Med, 2020, 46(1): 97-106. DOI: 10.3892/ijmm.2020.4577. doi: 10.3892/ijmm.2020.4577
[29]	Chen DT, Pan JH, Chen YH, et al. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target[J]. Br J Anaesth, 2019, 122(6): e157-e167. DOI: 10.1016/j.bja.2018.09.030. doi: 10.1016/j.bja.2018.09.030 pmid: 30915986
[30]	Tang B, Li Y, Yuan S, et al. Upregulation of the δ opioid receptor in liver cancer promotes liver cancer progression both in vitro and in vivo[J]. Int J Oncol, 2013, 43(4): 1281-1290. DOI: 10.3892/ijo.2013.2046. doi: 10.3892/ijo.2013.2046 pmid: 23903826
[31]	Akkız H, Bayram S, Bekar A, et al. Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma[J]. Mol Cell Biochem, 2011, 347(1/2): 201-208. DOI: 10.1007/s11010-010-0629-9. doi: 10.1007/s11010-010-0629-9
[32]	Wang RD, Zhu JY, Zhu Y, et al. Perioperative analgesia with parecoxib sodium improves postoperative pain and immune function in patients undergoing hepatectomy for hepatocellular carcinoma[J]. J Eval Clin Pract, 2020, 26(3): 992-1000. DOI: 10.1111/jep.13256. doi: 10.1111/jep.13256
[33]	Yeh CC, Lin JT, Jeng LB, et al. Nonsteroidal anti-inflammatory drugs are associated with reduced risk of early hepatocellular carcinoma recurrence after curative liver resection: a nationwide cohort study[J]. Ann Surg, 2015, 261(3): 521-526. DOI: 10.1097/SLA.0000000000000746. doi: 10.1097/SLA.0000000000000746
[34]	Takami Y, Eguchi S, Tateishi M, et al. A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment[J]. Hepatol Int, 2016, 10(5): 799-806. DOI: 10.1007/s12072-016-9704-y. doi: 10.1007/s12072-016-9704-y pmid: 26846471
[35]	Chen P, Luo X, Dai G, et al. Dexmedetomidine promotes the pro-gression of hepatocellular carcinoma through hepatic stellate cell activation[J]. Exp Mol Med, 2020, 52(7): 1062-1074. DOI: 10.1038/s12276-020-0461-6. doi: 10.1038/s12276-020-0461-6
[36]	Zhou L, Li J, Liu X, et al. Dexmedetomidine promotes apoptosis and suppresses proliferation of hepatocellular carcinoma cells via microRNA-130a/EGR1 axis[J]. Cell Death Discov, 2022, 8(1): 31. DOI: 10.1038/s41420-021-00805-5. doi: 10.1038/s41420-021-00805-5 pmid: 35046398
[37]	Huang L, Qin C, Wang L, et al. Effects of dexmedetomidine on immune response in patients undergoing radical and reconstructive surgery for oral cancer[J]. Oncol Lett, 2021, 21(2): 106. DOI: 10.3892/ol.2020.12367. doi: 10.3892/ol.2020.12367 pmid: 33376539
[38]	Wang K, Li C. Effects of dexmedetomidine on inflammatory factors, T lymphocyte subsets and expression of NF-κB in peripheral blood mononuclear cells in patients receiving radical surgery of colon carcinoma[J]. Oncol Lett, 2018, 15(5): 7153-7157. DOI: 10.3892/ol.2018.8205. doi: 10.3892/ol.2018.8205 pmid: 29725437
[39]	Tai YH, Wu HL, Mandell MS, et al. The association of allogeneic blood transfusion and the recurrence of hepatic cancer after surgical resection[J]. Anaesthesia, 2020, 75(4): 464-471. DOI: 10.1111/anae.14862. doi: 10.1111/anae.14862 pmid: 31573678
[40]	Chen GX, Qi CY, Hu WJ, et al. Perioperative blood transfusion has distinct postsurgical oncologic impact on patients with different stage of hepatocellular carcinoma[J]. BMC Cancer, 2020, 20(1): 487. DOI: 10.1186/s12885-020-06980-5. doi: 10.1186/s12885-020-06980-5
[41]	Xun Y, Tian H, Hu L, et al. The impact of perioperative allogeneic blood transfusion on prognosis of hepatocellular carcinoma after radical hepatectomy: a systematic review and meta-analysis of cohort studies[J]. Medicine (Baltimore), 2018, 97(43): e12911. DOI: 10.1097/MD.0000000000012911. doi: 10.1097/MD.0000000000012911
[42]	Aguilar-Nascimento JE, Zampieri-Filho JP, Bordin JO. Implications of perioperative allogeneic red blood cell transfusion on the immune-inflammatory response[J]. Hematol Transfus Cell Ther, 2021, 43(1): 58-64. DOI: 10.1016/j.htct.2020.03.003. doi: 10.1016/j.htct.2020.03.003 pmid: 32532624
[43]	Rodieck W, Hallensleben M, Robert J, et al. Impact of periopera-tive blood transfusions on postoperative renal function and survival after resection of colorectal liver metastases[J]. World J Surg Oncol, 2022, 20(1): 100. DOI: 10.1186/s12957-022-02559-5. doi: 10.1186/s12957-022-02559-5 pmid: 35354485
[44]	Nakaseko Y, Haruki K, Shiba H, et al. Impact of fresh frozen plasma transfusion on postoperative inflammation and prognosis of colorectal liver metastases[J]. J Surg Res, 2018, 226: 157-165. DOI: 10.1016/j.jss.2017.09.030. doi: S0022-4804(17)30628-5 pmid: 29661282
[45]	Yang T, Lu JH, Lau WY, et al. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: a propensity score matching analysis[J]. J Hepatol, 2016, 64(3): 583-593. DOI: 10.1016/j.jhep.2015.10.012. doi: 10.1016/j.jhep.2015.10.012 pmid: 26596543
[46]	Tian YL, Ji JJ, Chen LN, et al. Risk factors for long-term prognosis of hepatocellular carcinoma patients after anatomic hepatectomy[J]. World J Clin Cases, 2020, 8(4): 713-722. DOI: 10.12998/wjcc.v8.i4.713. doi: 10.12998/wjcc.v8.i4.713
[47]	Liu Z, Wang Y, Dou C, et al. Hypoxia-induced up-regulation of VASP promotes invasiveness and metastasis of hepatocellular carcinoma[J]. Theranostics, 2018, 8(17): 4649-4663. DOI: 10.7150/thno.26789. doi: 10.7150/thno.26789 pmid: 30279729
[48]	Yi J, Lei Y, Xu S, et al. Intraoperative hypothermia and its clinical outcomes in patients undergoing general anesthesia: national study in China[J]. PLoS One, 2017, 12(6): e0177221. DOI: 10.1371/journal.pone.0177221. doi: 10.1371/journal.pone.0177221
[49]	Yu H, Luo Y, Peng H, et al. The predicting value of postoperative body temperature on long-term survival in patients with rectal cancer[J]. Tumour Biol, 2015, 36(10): 8055-8063. DOI: 10.1007/s13277-015-3535-7. doi: 10.1007/s13277-015-3535-7
[50]	Zhang B, Wang Y, Zhao Z, et al. Temperature plays an essential regulatory role in the tumor immune microenvironment[J]. J Biomed Nanotechnol, 2021, 17(2): 169-195. DOI: 10.1166/jbn.2021.3030. doi: 10.1166/jbn.2021.3030 pmid: 33785090